Wird geladen...
Hormonal regulation of Semaphorin 7a in ER+ breast cancer drives therapeutic resistance
Approximately 70% of all breast cancers are estrogen receptor positive (ER+BC) and endocrine therapy has improved survival for patients with ER+BC. However, up to half of these tumors recur within 20 years. Recurrent ER+BCs develop resistance to endocrine therapy; thus, novel targets are needed to t...
Gespeichert in:
| Veröffentlicht in: | Cancer Res |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7878309/ https://ncbi.nlm.nih.gov/pubmed/33122307 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-20-1601 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|